Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions

Bortezomib (Velcade) is approved by the FDA for IV or SC injection in select patients with multiple myeloma or mantle cell lymphoma. The SC route functions as an alternative to IV administration for patients with poor IV access. Learn about effective strategies used to reduce injection site reaction...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurtin, Sandra, Knop, Carol S., Milliron, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093357/
https://www.ncbi.nlm.nih.gov/pubmed/25031973
Descripción
Sumario:Bortezomib (Velcade) is approved by the FDA for IV or SC injection in select patients with multiple myeloma or mantle cell lymphoma. The SC route functions as an alternative to IV administration for patients with poor IV access. Learn about effective strategies used to reduce injection site reactions that can occur with SC delivery.

Ejemplares similares